A selective dopamine D4 receptor antagonist, NRA0160 : A preclinical neuropharmacological profile

Life Sciences

Volumn 65, Issue 20, 1999, Pages 2109-2125

  Okuyama, Shigeru ^a   Kawashima, Naoya ^a   Chaki, Shigeyuki ^a   Yoshikawa, Ryoko ^a   Funakoshi, Takeo ^a   Ogawa, Shin ichi ^a   Suzuki, Yoshiko ^a   Ikeda, Yoko ^a   Kumagai, Toshihito ^a   Nakazato, Atsuro ^a   Nagamine, Masashi ^b   Tomisawa, Kazuyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b NIHON NOHYAKU CO LTD   (Japan)

Author keywords

Antipsychotic activities; Apomorph ine; Clozapine; Dopamine D4 receptor antagonist; Methamphetamine; NRA0160; Pharmacology; Phencyclidine

Indexed keywords

2 CARBAMOYL 4 (4 FLUOROPHENYL) 5 [2 [4 (3 FLUOROBENZYLIDENE)PIPERIDIN 1 YL]ETHYL]THIAZOLE; APOMORPHINE; CLOZAPINE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; METHAMPHETAMINE; NEUROLEPTIC AGENT; PHENCYCLIDINE; UNCLASSIFIED DRUG; 5 [2 [4 (3 FLUOROBENZYLIDENE) 1 PIPERIDINYL]ETHYL] 4 (4 FLUOROPHENYL)THIAZOLE 2 CARBOXAMIDE; DOPAMINE 2 RECEPTOR; DRD4 PROTEIN, MOUSE; DRD4 PROTEIN, RAT; PIPERIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CATALEPSY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RECEPTOR BINDING; GUINEA PIG; HUMAN; HUMAN CELL; LOCOMOTION; MALE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PREPULSE INHIBITION; RAT; STEREOTYPY; STRUCTURE ACTIVITY RELATION; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CHEMICALLY INDUCED DISORDER; DRUG SCREENING; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; MAZE TEST; METABOLISM; STARTLE REFLEX; SWIMMING; WISTAR RAT;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN; CATALEPSY; CLOZAPINE; DRUG EVALUATION, PRECLINICAL; LOCOMOTION; MALE; MAZE LEARNING; METHAMPHETAMINE; MICE; MICE, INBRED ICR; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; STARTLE REACTION; STEREOTYPED BEHAVIOR; SWIMMING; THIAZOLES;

EID: 0033536508     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(99)00476-2     Document Type: Article

References (50)

1. A.M. Ariano, J. Wang, K.L. Noblett, E.R. Lanson and D.R. Sibley, Brain Res. 752 26-34 (1997).
2. L.J. Bristow, N. Collinson, G.P. Cook, N. Curtis, S.B. Freedman, J.J. Kulagowski, P.D. Leeson, S. Patel, C.I. Ragan, M. Ridgill, K.L. Saywell, and M.D. Tricklebank, J. Pharmacol. Exp Ther. 283 1256-1263 (1997).
3. M. Bubser and M. Koch, Psychopharmacol. 113 487-492 (1994).
4. P. Boyer, Y. Lecrubier. and A.J. Puech, Mod. Pro. Pharmacopsychiatry 24 152-174 (1990).
5. D.E. Casey, Psychopharmacol. 99 S47-S53 (1989).
6. Y.C. Cheng and W.H. Prusoff, Biochem. Pharmacol. 22 3099-3108 (1973).
7. P. Chomczynski. and N. Sacchi, Anal. Biochem. 162 156-159 (1987).
8. M.C. Defagot and M.C. Antonelli, Neurochem. Res. 22 401-407 (1997).
9. M.C. Defagot, E.L. Malchiodi, M.J. Villar and M.C. Antonelli, Mol. Brain Res. 45 1-12 (1997).
10. J.L. Evenden and C.N. Ryan, Psychotropic Drugs of Abuse, ed. by D.J.K. Balfour (Ed), 1-21, Pergamon Press, New York (1990).
11. P.L. Felgner, T.R. Gadek, M. Holm, R. Roman, H.W. Chan, M. Wenz, J.P. Northrop, M.G. Ringold and M. Danielsen, Proc. Natl. Acad. Sci. USA, 84 7413-7417 (1987).
12. M.A. Geyer and D.L. Braff, Biol. Psychiatry 27 97A (1990).
13. M.A. Geyer, N.R. Swerdlow, R.S. Mansbach and D.L. Braff, Brain Res. Bull. 25 485-498 (1990).
14. J. Hirschowitz, R. Hitzemann, G. Burr. and A. Maurset, Neuropsychopharmacol. 5 103-113 (1991)
15. D.C. Hoffman and H. Donovan, Psychopharmacol. 120 128-133 (1995).
16. K.R. Jarvie, M. Tiberi, C. Silvia, J.A. Gingrich and M.G. Carbon, J. Recept. Res. 13 573-590 (1993).
17. D.C. Javitt and S.R. Zukin, Am. J. Psychiatry 148 1301-1308 (1991).
18. M.D. Johnson, B.M. Siegel and A.A. Carr, Naunyn-Schmiedeberg's Arch. Pharmacol. 354 205-209 (1996).
19. 4 Dopamine Antagonist Group, Arch. Gen. Psychiatry 54 567-572 (1997).
20. R.A. Lahti, D.L. Evans, N.C. Stratman and L.M. Figur, Eur. J. Pharmacol. 236 483-486 (1993).
21. D.F. Levinson, Clin. Ther. 13 326-352 (1991).
22. M.S. Lidow and P.S. Goldman-Rakic, J. Pharmacol. Exp. Ther. 283 939-946 (1997).
23. O.H. Lowry, N.J. Rosebrough, A.L. Farr and R.L. Randall, J. Bio. Chem. 193 265-275 (1951).
24. R.S. Mansbach, E,.W. Rooks, M.A. Sanner and S.H. Zorn, Psychopharmacol. 135 194-200 (1998).
25. A. Mansour and S.J. Watson, Psychopharmacology: The Fourth Generation of Progress, F.E Bloom and D.V. Kupfer (Eds), 207-219, Raven Press, New York (1995).
26. K.M. Merchant, G.S. Gill, D.W. Harris, R.M. Huff, M.J. Eaton, K. Lookingland, B.S. Lutzke, R.S. McCall, M.F. Piercey, P.j.k.d. Schreur, V.H. Sethy, M.W. Smith, K.A. Svensson, A.H. Tang, P.F. Vonvoigtlander and R.E. Tenbrink, J. Pharmacol. Exp. Ther. 279 1392-1403 (1996).
27. L. Mrzljak, C. Bergson, M. Pappy, R. Huff, R. Levenson and P.S. Goldman-Rakic, P.S. (1996) Nature 281 245-248 (1996).
28. A.M. Murray, T.M. Hyde, M.B. Knable, M.M. Herman, L.B. Bigelow, J.M. Carter, D.R. Weinberger and J.E. Kleinman, J. Neurosci. 15 2186-2191 (1995).
29. S. Ogawa, S. Okuyama, H. Araki, A. Nakazato and S. Otomo, Life Sci. 55 1605-1610 (1994).
30. S. Ogawa, S. Okuyama, H. Araki and S. Otomo, Eur. J. Pharmacol. 263 9-15 (1994).
31. S. Okuyama, S. Chaki, R. Yoshikawa, Y. Suzuki, S. Ogawa, Y. Imagawa, N. Kawashima, Y. Ikeda, T. Kumagai, A. Nakazato, M. Nagamine and K. Tomosawa, J. Pharmacol. Exp. Ther. 282 56-63 (1997).
32. S. Okuyama, Y. Imagawa, S. Ogawa, H. Araki, A. Ajima, M. Tanaka, M. Muramatsu, A. Nakazato, K. Yamaguchi, M. Yoshida and S. Otomo, Life Sci. 53 PL285-290 (1993).
33. S. Okuyama, S. Ogawa, A. Nakazato and S. Otomo, Neurosci. Letts. 189 60-62 (1995).
34. K.L. O'Malley, S. Harmon, L. Tang and R.D. Todd, New Biol. 4 137-146 (1992).
35. S. Patel, S. Freedman, K.L. Chapman, F. Emms, A.E. Fletcher, M. Knowles, R. Marwood, G. McAllister, J. Myers, S. Patel, N. Curtis, J.J. Kulagowski, P.D. Leeson, M. Ridgill, M. Graham, S. Matheson, D. Rathbone, A.L. Watt, L.J. Bristow, N.M.J. Rupniak, E. Baskin, J.J. Lynch and C.I. Ragan, J. Pharmacol. Exp. Ther. 283 636-647 (1997).
36. G.P. Reynolds, Developments in the compound treatment of schizophrenia. Trends Pharmacol. Sci. 13 116-121 (1992).
37. G.P. Reynolds and S.L. Mason, J. Neurochem. 63 1576-1577 (1995).
38. A. Sciolla and D.V. Jeste, Int. J. Psychiatry Clin. Practice 2 S27-S34 (1998).
39. P. Seeman, H.-C. Guan and H.H.M. Van Tol, Nature 365 441-445 (1993).
40. P. Seeman, H.-C. Guan and H.H.M. Van Tol, Eur. J. Pharmacol. 286 R3-R5 (1995).
41. P. Sokoloff, B. Giros, M.-P. Martres, M.-L. Bouthenet and J.-C. Schwartz, Nature 347 146-151 (1990).
42. N.C. Stefanis, J.N. Bresnick, R.W. Kerwin, W.N. Schofield and G. McAllister, Mol. Brain Res. 53 112-119 (1998).
43. T. Sumiyoshi, C.A. Stockmeier, J.C. Overholser, P.A. Thompson and H.Y. Meltzer, Brain Res. 681 109-116 (1995).
44. N.R. Swerdlow, V.A. Keith, D.L. Braff and M.A. Geyer, J. Pharmacol. Exp. Ther. 256 530-536 (1991).
45. N.R. Swerdlow, D.L. Braff, N. Taid and M.A. Geyer, Arch. Gen. Psychiatry 51 139-154 (1994).
46. Y. Takebe, M. Seiki, J. Fujisawa, P. Hoy, K. Yokota, K. Arai, M. Yoshida and N. Arai, Mol. Cell. Biol. 8 466-472 (1988).
47. C.A. Tamminga, G.K. Thaker, R. Buchanan, B. Kirkpatrick, D.L. Alphs, T.N. Chase and W.T. Carpenter, Arch. Gen. Psychiatry 49 522-530 (1992).
48. F.I. Tarazi, A. Campbell, A., S.K. Yeghiayan and R.J. Baldessarini, Neuroscience 83 169-176 (1998).
49. F.I. Tarazi, N.S. Kula and R.J. Baldessarini, Neuroreport 8 3423-3426 (1997).
50. P.B.M.W.H. Timmermans, F. Karamat Ali, H.Y. Kwa, A.M.C. Schoop, F.P. Slothorst-Grisdijk and P.A. Van Zwieten, Mol. Pharmacol. 20, 295-301 (1981).